Status:
UNKNOWN
Exosomal microRNAs as a Biomarker in Panic Disorder and in Response to CBT
Lead Sponsor:
Hebrew University of Jerusalem
Collaborating Sponsors:
Hadassah Medical Organization
Conditions:
Panic Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Cognitive behavior therapy (CBT) has long been known as an effective treatment for anxiety disorders, either when given by a therapist or when self-administered through a computer program. However, th...
Detailed Description
Cognitive Behavior Therapy (CBT) is an evidence-based treatment, commonly used for treating anxiety disorders. Patients with anxiety disorders are characterized by having cognitive distortions regardi...
Eligibility Criteria
Inclusion
- Principal DSM-5 primary diagnosis of panic disorder and/or agoraphobia.
- Aged 18 years or older.
- PD duration of at least 3 months.
- If participant is on on medications for PD, the dosage has to remain constant for 3 months prior to the start of treatment and cannot be increased during treatment.
- The participant must have access to the internet and be willing to use it.
Exclusion
- Substance abuse or dependence within the last 6 months.
- Active suicide potential within the last 6 months.
- Any current or history of psychosis or bipolar I disorder.
- Currently in weekly or biweekly psychotherapy.
- History of a complete course of panic focused CBT
Key Trial Info
Start Date :
March 24 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 24 2021
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04029740
Start Date
March 24 2019
End Date
December 24 2021
Last Update
February 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hebrew University of Jerusalem
Jerusalem, Israel, 9190501